Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Villarroel 170, Edifici Helios, despatx 8, 08036, Barcelona, Spain.
Ciber Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Eur J Nutr. 2019 Jun;58(4):1561-1568. doi: 10.1007/s00394-018-1691-4. Epub 2018 Apr 19.
The activity of stearoyl-CoA desaturase-1 (SCD1) is increased in non-alcoholic fatty liver disease (NAFLD). Polyunsaturated fatty acids (PUFA) inhibit SCD1, but clinical studies on whether all dietary PUFA species are equal in SCD1 inhibition are scarce. Serum phospholipids are an objective proxy of dietary intake of plant-derived PUFA (C18:2n-6, C18:3n-3) and marine-derived PUFA (C20:5n-3, C22:6n-3). In 355 participants with primary dyslipidemia, we cross-sectionally investigated whether the presumed association between surrogate markers of NAFLD and SCD1 activity is mediated by intake of PUFA, and, if it is, what PUFA species are relevant in this regard.
We determined the fatty acid profile of serum phospholipids by gas chromatography, and used the ratio C16:1n-7/C16:0 as a marker of SCD1 activity. NAFLD was diagnosed by values ≥ 60 in the fatty liver index (FLI), a surrogate recently validated against ultrasonography.
FLI ≥ 60 was detected in 37.5% (n = 133) of study participants. In a multivariate model, SCD1 activity showed an expected significant association with the risk of NAFLD, with odds ratio (OR) (95% confidence interval) of 1.44 (1.04-2.01) for each 0.01 increase. In a model further allowing the stepwise inclusion of plant-derived PUFA, marine-derived PUFA, and total PUFA (vegetable + marine), total PUFA replaced SCD1 activity as a significant (inverse) association of NAFLD, with OR 0.89 (0.81-0.99).
Total PUFA, regardless of their origin, mediates the relationship between SCD1 activity and NAFLD. This provides a new insight in the protective effects of PUFA against NAFLD, heretofore mostly focussed on PUFA species from marine origin.
硬脂酰辅酶 A 去饱和酶-1(SCD1)的活性在非酒精性脂肪性肝病(NAFLD)中增加。多不饱和脂肪酸(PUFA)抑制 SCD1,但关于所有膳食 PUFA 种类在 SCD1 抑制方面是否相等的临床研究很少。血清磷脂是植物源性 PUFA(C18:2n-6、C18:3n-3)和海洋源性 PUFA(C20:5n-3、C22:6n-3)膳食摄入的客观替代物。在 355 名原发性血脂异常患者中,我们进行了横断面研究,以调查假定的 NAFLD 替代标志物与 SCD1 活性之间的关联是否通过 PUFA 摄入介导,如果是,在这方面哪些 PUFA 种类是相关的。
我们通过气相色谱法确定血清磷脂的脂肪酸谱,并使用 C16:1n-7/C16:0 比值作为 SCD1 活性的标志物。NAFLD 通过脂肪肝指数(FLI)≥60 来诊断,这是一种最近经超声验证的替代指标。
37.5%(n=133)的研究参与者检测到 FLI≥60。在多变量模型中,SCD1 活性与 NAFLD 风险呈预期显著相关,每增加 0.01,比值比(OR)(95%置信区间)为 1.44(1.04-2.01)。在进一步允许逐步纳入植物源性 PUFA、海洋源性 PUFA 和总 PUFA(植物+海洋)的模型中,总 PUFA 取代 SCD1 活性作为 NAFLD 的显著(负相关)关联物,OR 为 0.89(0.81-0.99)。
总 PUFA,无论其来源如何,介导 SCD1 活性与 NAFLD 之间的关系。这为 PUFA 对 NAFLD 的保护作用提供了新的见解,迄今为止,这主要集中在海洋源性 PUFA 上。